Travere Therapeutics, Inc. Total Revenue

• Travere Therapeutics, Inc. showed an increase of +110.5% in Total Revenue from 2024 to 2025.
• This data is from Travere Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
• XBRL data for this metric is available from 2011 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q4 2010: $0.00 | Q2 2011: $0.00 | Q3 2011: $0.00 | Q4 2011: $0.00 | Q2 2012: $0.00 | Q3 2012: $0.00 | Q4 2012: $0.00 | Q1 2017: $33.62 million | Q2 2017: $38.80 million | Q3 2017: $40.34 million | Q4 2017: $42.18 million | Q1 2018: $38.43 million | Q2 2018: $41.34 million | Q3 2018: $40.71 million | Q4 2018: $43.77 million | Q1 2019: $39.57 million | Q2 2019: $44.71 million | Q3 2019: $44.37 million | Q4 2019: $46.69 million | Q1 2020: $47.77 million | Q2 2020: $48.43 million | Q3 2020: $51.14 million | Q4 2020: $50.98 million | Q1 2021: $47.41 million | Q2 2021: $54.62 million | Q3 2021: $68.22 million | Q1 2022: $23.41 million | Q2 2022: $28.63 million | Q3 2022: $28.08 million | Q4 2022: $29.34 million | Q1 2023: $30.89 million | Q2 2023: $32.20 million | Q3 2023: $37.10 million | Q4 2023: $45.06 million | Q1 2024: $41.37 million | Q2 2024: $54.12 million | Q3 2024: $62.90 million | Q1 2025: $81.73 million | Q2 2025: $114.45 million | Q3 2025: $164.86 million.
• Historical annual values: Fiscal year 2025: $490.73 million | Fiscal year 2024: $233.18 million | Fiscal year 2023: $145.24 million | Fiscal year 2022: $109.46 million | Fiscal year 2021: $131.84 million | Fiscal year 2020: $198.32 million | Fiscal year 2019: $175.34 million | Fiscal year 2018: $164.25 million | Fiscal year 2017: $154.94 million | Fiscal year 2016: $133.59 million | Fiscal year 2012: $0.00 | Fiscal year 2011: $0.00.
• Data sourced from SEC EDGAR public filings as of August 7, 2026.

Last verified: August 7, 2026